Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0PCQPN
ADC Name	Anti-CXCR4 ADC 519
Synonyms	Anti-CXCR4-ADC-519 Click to Show/Hide
Drug Status	Investigative
Indication	In total 5 Indication(s) Acute lymphocytic leukemia [ICD11:2B33] Investigative Acute myeloid leukaemia [ICD11:2A60] Investigative Multiple myeloma [ICD11:2A83] Investigative Non Hodgkin lymphoma [ICD11:2B33] Investigative Non-small cell lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	Anti-CXCR4 mAb m17		Antibody Info
Antigen Name	C-X-C chemokine receptor type 4 (CXCR4)		Antigen Info
Payload Name	Auristatin 0101		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	AcLys-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation conjugation through nucleophilic lysines.
Combination Type	AcLys-VC-PABC-0101

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	4.7	nM	Jurkat cells	T acute lymphoblastic leukemia

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.70 nM	High CXCR4 expression (CXCR4+++)
Method Description	Cells were seeded in a culture-treated 96-well clear plate and incubated at 37°C under 5% CO₂ for 24h. Serially diluted samples (50L) were added to each well and the plate was incubated at 37°C for 72h.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

References

Ref 1	Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates. Sci Rep. 2019 Feb 21;9(1):2443. doi: 10.1038/s41598-019-38745-x.